Painimation: An innovative, technology-based method for measuring pain quality, location and severity in sickle cell disease

项目摘要 疼痛是患有镰状细胞病（SCD）的成年人进入医疗保健系统的首要原因。到 充分治疗疼痛首先需要准确的评估，然而，没有有效的疼痛措施， 捕捉SCD疼痛的多维现象。疼痛的一维测量，例如 数值0-10的等级具有有限的效用，并且对于指导治疗无效。多维疼痛工具 它们既长又复杂，使患者难以使用。没有人试图建立一个多- 三维测量来评估和分类SCD中的疼痛。该项目的长期目标是开发一个 全面的，以患者为中心的疼痛评估工具，将改善患者与提供者的沟通，疼痛 诊断和治疗疼痛。拟议的R 03测试了一种新的电子疼痛评估工具， 疼痛，允许患者使用动画和图形图像来传达他们的疼痛。我们 主要目的是确定疼痛是否可被患者接受，并可用作有效的SCD 疼痛评估工具。我们假设疼痛治疗比其他治疗更容易被患者接受和使用。 标准尺度。在目标1中，我们将确定Painimation用于沟通的可用性和可接受性 并评估成人SCD患者的疼痛。我们将与其他经过验证的疼痛量表（ 0-10视觉模拟量表、PainDETECT和麦吉尔疼痛问卷）对70名成人SCD患者进行了研究。 横断面调查研究。对于每项指标，我们将评估可用性、患者满意度和感知 将疼痛传达给供应商的有用性。在目标2中，我们将确定是否使用 疼痛与患者的生活质量和临床结局相关。我们将测试 疼痛与患者报告的生活质量（ASCQ-Me）和客观健康结局（即器官损伤， 疼痛的急性护理访视次数），以确定疼痛是否是临床试验中可行的结局指标 测试疼痛干预。最后，在探索性目标3中，我们将测试疼痛是否可以区分 SCD疼痛类型（例如神经性与伤害性）。这项研究意义重大，因为它将导致 创建一个简短，准确，以用户为中心的疼痛评估工具，用于SCD。我们的团队包括 IT、UX设计、疼痛和测量开发方面的专家。扩展疼痛，一种新的技术- 基于疼痛评估工具，用于SCD直接关系到我的K23项目，并将 提升我作为独立研究者的潜力，进行大规模（R 01）研究， 疼痛干预对健康结果的影响。长期的、改进的结果衡量将增加 我们检测移动的技术提供的行为干预的效果的能力。

PROJECT ABSTRACT Pain is the number one reason adults with sickle cell disease (SCD) access the healthcare system. To adequately treat pain first requires accurate assessment, however, there are no pain measures that effectively capture the multidimensional phenomenon of SCD pain. One-dimensional measures of pain, such as the numerical 0-10 scale, have limited utility and are ineffective for guiding treatment. Multi-dimensional pain tools are long and complex, making them difficult for patients to use. There have been no attempts to create a multi- dimensional measure to assess and classify pain in SCD. The long-term goal of this project is to develop a comprehensive, patient-centered, pain assessment tool, that will improve patient-provider communication, pain diagnosis, and treatment of pain. The proposed R03 tests a novel electronic pain assessment tool called Painimation, that allows patients to use animations and graphical images to communicate their pain. Our primary objective will be to determine if Painimation is acceptable to patients and can be used as a valid SCD pain assessment tool. We hypothesize that Painimation will be more usable and acceptable to patients than standard scales. In Aim 1, we will determine the usability and acceptability of Painimation for communicating and assessing pain among adults with SCD. We will test Painimation alongside other validated pain scales (the 0-10 visual analog scale, PainDETECT, and the McGill Pain Questionnaire) among 70 adults with SCD in a cross-sectional survey study. For each measure, we will evaluate usability, patient satisfaction, and perceived usefulness for communicating pain to providers. In Aim 2, we will determine whether pain assessment using Painimation is associated with patients' quality of life and clinical outcomes. We will test the association of Painimation with patient-reported quality of life (ASCQ-Me) and objective health outcomes (i.e. organ damage, number of acute care visits for pain) to determine if Painimation is a viable outcome measure in clinical trials testing pain interventions. Finally, in an exploratory Aim 3, we will test whether Painimation can differentiate SCD pain types (e.g. neuropathic vs nociceptive). The proposed research is significant because it will lead to the creation of a brief, accurate, and user-centered pain assessment tool for use in SCD. Our team includes experts in IT, UX design, pain, and measurement development. Expanding Painimation, a novel, technology- based pain assessment tool, for use in SCD directly relates to and results from my K23 project and will advance my potential as an independent investigator to conduct large-scale (R01) studies examining the impact of pain interventions on health outcomes. Long-term, improved outcomes measurement will increase our ability to detect the effects of our mobile technology-delivered behavioral interventions.